Market capitalization | $1.50b |
Enterprise Value | $1.63b |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 8.01 |
P/S ratio (TTM) P/S ratio | 7.39 |
P/B ratio (TTM) P/B ratio | negative |
Revenue growth (TTM) Revenue growth | -2.96% |
Revenue (TTM) Revenue | $203.45m |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
15 Analysts have issued a Travere Therapeutics Inc forecast:
15 Analysts have issued a Travere Therapeutics Inc forecast:
Sep '24 |
+/-
%
|
||
Revenue | 203 203 |
3%
3%
|
|
Gross Profit | 150 150 |
3%
3%
|
|
EBITDA | -236 -236 |
17%
17%
|
EBIT (Operating Income) EBIT | -280 -280 |
15%
15%
|
Net Profit | -352 -352 |
12%
12%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Travere Therapeutics, Inc. is a biopharmaceutical company. It engages in the identification, development, commercialization, and distribution of therapies to people living with rare diseases. Its products include Chenodal, Cholbam, and Thiola. The company was founded by Martin Shkreli on February 8, 2008 and is headquartered in San Diego, CA.
Head office | United States |
CEO | Eric Dube |
Employees | 380 |
Founded | 2008 |
Website | www.travere.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.